Key facts
- Vironexis Biotherapeutics’s last known valuation is $125.0M (Feb 2025).
- It has raised $52.0M; the latest was Later Stage VC ($26.0M) in Mar 2026.
- Notable investors include Capital Factory, Drive Capital, Future Ventures (San Francisco), Rev1 Ventures, Moonshots Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vironexis Biotherapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Vironexis Biotherapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vironexis Biotherapeutics
Developer of a cancer treatment biotechnology designed to offer AAV-delivered T-cell Immunotherapy. The company's gene therapy technology enables the creation of off-the-shelf, single-dose gene therapies, enabling healthcare professionals to help cancer patients achieve better outcomes through T-cell-mediated cancer killing.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2021
- Employees
- 12
- Website
- vironexis.com/
- Ownership
- Privately Held (backing)
Vironexis Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vironexis Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vironexis Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.